Table 5.
Factors associated with HCV service provision at DCRs/SIFs - bi-variate logistic regression
| (1) Provide HCV testing onsite (n = 32; 665%) OR (standard error), p-value |
(2) Provide liver monitoring or disease management onsite (n = 25; 51%) OR (standard error), p-value |
(3) Provide HCV treatment onsite or planning to provide in near future (n = 10; 20%) OR (standard error), p-value |
|
|---|---|---|---|
| Operational | |||
| Country (Netherlands) | 0.15* (0.13), 0.02 | 1.48 (0.37), 0.11 | 1.39 (0.42), 0.26 |
| Operated by the government | 0.89 (0.58), 0.86 | 0.53 (0.33), 0.31 | 1.57 (1.23), 0.57 |
| Funding from local government | 0.55 (0.41), 0.41 | 0.76 (0.52), 0.69 | 0.64 (0.53), 0.59 |
| Co-located with another program | 1.38 (0.90), 0.61 | 1.67 (1.02), 0.40 | 2.84 (2.50), 0.21 |
| Stand-alone facility with other services nearby | 2.01 (1.51), 0.53 | 1.17 (0.76), 0.81 | 0.69 (0.62), 0.68 |
| Staff-Related | |||
| Employing a nurse | 2.08 (1.60), 0.34 | 12.38** (13.92), 0.01 | 0.70 (0.64), 0.70 |
| Employing a medical doctor | 1.48 (0.98), 0.55 | 8.00*** (5.66), 0.00 | 14.58*** (16.41), 0.00 |
| Employing peer workers | 0.88 (0.70), 0.87 | 0.47 (0.34), 0.29 | 1.43 (1.31), 0.70 |
| Higher than median number of paid staff on average day (> 4) | 1.20 (0.80), 0.80 | 1.22 (0.77), 0.75 | 2.00 (1.62), 0.39 |
| Client-Related | |||
| Higher than median number of attendees per day (> 78) | 1.42 (1.04), 0.63 | 0.62 (0.43), 0.49 | 2.14 (2.02), 0.41 |
| Higher than median % of clients tested for HCV (> 80%) | 1.98 (1.38), 0.32 | 0.38 (0.26), 0.15 | 0.51 (0.38), 0.36 |
| Higher than median % of clients estimated as HCV positive (> 60%) | 0.83 (0.57), 0.79 | 0.60 (0.40), 0.44 | 1.00 (0.75), 1.00 |
| Service-Related | |||
| Provide naloxone onsite | 3.02 (2.25), 0.12 | 1.67 (1.07), 0.42 | 0.49 (0.43), 0.40 |
| Provide HIV counselling onsite | 2.57 (1.77), 0.17 | 4.09* (2.90), 0.04 | 3.36 (3.78), 0.23 |
| Provide HIV testing onsite | 44.57*** (50.06), 0.00 | 7.00*** (4.75), 0.00 | 2.84 (2.50), 0.21 |
| Provide OST onsite | 2.45 (2.11), 0.27 | 5.40* (4.62), 0.03 | 4.29 (3.52), 0.08 |
| Provide HBV vaccination onsite | 7.29** (6.15), 0.01 | 6.67*** (4.67), 0.00 | 1.47 (1.15), 0.62 |
| Higher than median no of spaces for drug use (> 10) | 0.63 (0.43), 0.49 | 0.62 (0.39), 0.44 | 2.97 (2.68), 0.21 |
*statistically significant difference (country group vs. all other countries) on p < 0.05 level; **statistically significant difference on p < 0.01 level; ***statistically significant difference on p = 0.00 level